A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases
Joint Authors
Lotem, Michal
Melnik, Idit
Yoffe, Boris
Source
Case Reports in Oncological Medicine
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-12-23
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Vemurafenib is approved by the FDA for the management of unresectable or metastatic melanoma.
However, its role as a neoadjuvant therapy has not been determined.
We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.
American Psychological Association (APA)
Melnik, Idit& Lotem, Michal& Yoffe, Boris. 2013. A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine،Vol. 2013, no. 2013, pp.1-3.
https://search.emarefa.net/detail/BIM-498661
Modern Language Association (MLA)
Melnik, Idit…[et al.]. A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine No. 2013 (2013), pp.1-3.
https://search.emarefa.net/detail/BIM-498661
American Medical Association (AMA)
Melnik, Idit& Lotem, Michal& Yoffe, Boris. A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine. 2013. Vol. 2013, no. 2013, pp.1-3.
https://search.emarefa.net/detail/BIM-498661
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-498661